ES2259188T3 - Complejos de ligando de acido nucleico de factor de crecimiento endotelial vascular (vegf). - Google Patents

Complejos de ligando de acido nucleico de factor de crecimiento endotelial vascular (vegf).

Info

Publication number
ES2259188T3
ES2259188T3 ES97912811T ES97912811T ES2259188T3 ES 2259188 T3 ES2259188 T3 ES 2259188T3 ES 97912811 T ES97912811 T ES 97912811T ES 97912811 T ES97912811 T ES 97912811T ES 2259188 T3 ES2259188 T3 ES 2259188T3
Authority
ES
Spain
Prior art keywords
vegf
baselineskip
nucleic acid
ligand
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97912811T
Other languages
English (en)
Spanish (es)
Inventor
Nebojsa Janjic
Larry Gold
Paul G. Schmidt
Chandra Vargeese
Michael Willis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/739,109 external-priority patent/US5859228A/en
Priority claimed from US08/870,930 external-priority patent/US6168778B1/en
Priority claimed from US08/897,351 external-priority patent/US6051698A/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ES2259188T3 publication Critical patent/ES2259188T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES97912811T 1996-10-25 1997-10-17 Complejos de ligando de acido nucleico de factor de crecimiento endotelial vascular (vegf). Expired - Lifetime ES2259188T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US739109 1996-10-25
US08/739,109 US5859228A (en) 1995-05-04 1996-10-25 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US08/870,930 US6168778B1 (en) 1990-06-11 1997-06-06 Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US870930 1997-06-06
US897351 1997-07-21
US08/897,351 US6051698A (en) 1997-06-06 1997-07-21 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes

Publications (1)

Publication Number Publication Date
ES2259188T3 true ES2259188T3 (es) 2006-09-16

Family

ID=27419245

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97912811T Expired - Lifetime ES2259188T3 (es) 1996-10-25 1997-10-17 Complejos de ligando de acido nucleico de factor de crecimiento endotelial vascular (vegf).

Country Status (18)

Country Link
EP (2) EP0957929B1 (enExample)
JP (2) JP3626503B2 (enExample)
KR (1) KR100514929B1 (enExample)
AT (1) ATE318143T1 (enExample)
AU (1) AU733674B2 (enExample)
CA (1) CA2269072C (enExample)
DE (3) DE122006000029I1 (enExample)
DK (1) DK0957929T3 (enExample)
ES (1) ES2259188T3 (enExample)
FR (1) FR06C0021I2 (enExample)
GE (1) GEP20094799B (enExample)
IL (2) IL129497A0 (enExample)
LU (1) LU91252I2 (enExample)
NL (1) NL300234I2 (enExample)
NZ (1) NZ334859A (enExample)
PT (1) PT957929E (enExample)
RU (1) RU2177950C2 (enExample)
WO (1) WO1998018480A1 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US6346611B1 (en) * 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
AU782620B2 (en) * 1991-06-10 2005-08-11 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
US6762290B1 (en) 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
KR20070086708A (ko) 1999-07-14 2007-08-27 알자 코포레이션 중성 지질중합체 및 그를 함유하는 리포솜 조성물
EP2351855A1 (en) * 2000-09-26 2011-08-03 Duke University RNA aptamers and methods for identifying the same
DK1438321T5 (da) * 2001-10-26 2011-02-21 Noxxon Pharma Ag Modificeret L-nukleinsyre
KR20050044372A (ko) * 2001-11-09 2005-05-12 아이테크 파마슈티컬즈, 인크. 눈의 혈관신생성 질환을 치료하는 방법
US7094410B2 (en) * 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
BR0313212A (pt) * 2002-07-24 2005-06-28 Hoffmann La Roche Aditivos de ácido de polialquileno glicol
ATE516366T1 (de) 2002-07-25 2011-07-15 Archemix Corp Regulierte aptamer-therapeutika
US9303262B2 (en) 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8039443B2 (en) 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
EP1570085A4 (en) * 2002-12-03 2007-07-25 Archemix Corp PROCESS FOR IN VITRO SELECTION OF 2'-SUBSTITUTED NUCLEIC ACIDS
RU2234097C1 (ru) * 2003-03-05 2004-08-10 Московский областной научно-исследовательский клинический институт Способ диагностики саркомы капоши
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
AU2004232848A1 (en) 2003-04-21 2004-11-04 Archemix Corp. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
CL2004001996A1 (es) * 2003-08-08 2005-05-06 Eyetech Pharmaceuticals Inc Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion.
EP3736335A1 (en) 2004-02-12 2020-11-11 Archemix LLC Aptamer therapeutics useful in the treatment of complement-related disorders
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
CA2562948A1 (en) * 2004-04-13 2005-11-24 (Osi) Eyetech, Inc. Enhanced biologically active conjugates
US7579450B2 (en) 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
KR20070101226A (ko) 2004-09-07 2007-10-16 아케믹스 코포레이션 앱타머의 약화학
EP3034089A1 (en) 2004-11-02 2016-06-22 Archemix LLC Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
KR20080025181A (ko) 2005-06-30 2008-03-19 아케믹스 코포레이션 완전 2'-변형된 핵산 전사체를 생성하기 위한 물질 및 방법
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
JP2009510182A (ja) * 2005-07-28 2009-03-12 （オーエスアイ）アイテツク・インコーポレーテツド シクリトールリンカーポリマー抱合体
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
KR100877824B1 (ko) 2005-11-11 2009-01-12 한국생명공학연구원 Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
CA2632417A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
JP2009519033A (ja) * 2005-12-16 2009-05-14 ディアト 核酸を細胞に送達するための細胞貫通ペプチド結合体
EP1970078A4 (en) * 2006-01-11 2010-11-17 Kyowa Hakko Kirin Co Ltd COMPOSITION INHIBITING THE EXPRESSION OF A TARGET GENE OF THE OCULAR GLOBE AND REMEDY FOR OCULAR GLOBE DISEASE
SG172686A1 (en) 2006-03-08 2011-07-28 Archemix Corp Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
PL2125007T3 (pl) 2007-02-07 2014-07-31 Univ California Koniugaty syntetycznych agonistów TLR i ich zastosowania
US20110229498A1 (en) 2008-05-08 2011-09-22 The Johns Hopkins University Compositions and methods for modulating an immune response
CN102341498B (zh) * 2008-12-04 2017-12-19 库尔纳公司 通过抑制血管内皮生长因子(vegf)的天然反义转录子治疗vegf相关的疾病
AU2010226434A1 (en) 2009-03-20 2011-10-13 Egen, Inc. Polyamine derivatives
US20120295811A1 (en) 2009-11-23 2012-11-22 Jean-Jacques Toulme Aptamers directed against the matrix protein-1 of type a influenza viruses and uses thereof
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
CA2811601A1 (en) * 2010-09-24 2012-03-29 Mallinckrodt Llc Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers
US20150337308A1 (en) 2012-04-11 2015-11-26 Chu De Bordeaux Matrix metalloproteinase 9 (mmp-9) aptamer and uses thereof
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
EP4170031A1 (en) 2012-10-23 2023-04-26 Caris Science, Inc. Aptamers and uses thereof
WO2014100434A1 (en) 2012-12-19 2014-06-26 Caris Science, Inc. Compositions and methods for aptamer screening
EP2977454B1 (en) 2013-03-22 2018-05-02 The University of Tokyo Aptamer to il-17 and use thereof
SG10201912985RA (en) 2013-07-12 2020-02-27 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
BR112016004153A2 (pt) 2013-08-28 2019-09-17 Caris Life Sciences Switzerland Holdings Gmbh "método para caracterizar uma doença ou distúrbio, kit, composição, método para gerar uma biblioteca de entrada, oligonucleotídeo, pluralidade de oligonucleotídeos e método para identificar um aptâmero
AU2015360496B2 (en) 2014-12-11 2021-09-30 Bayer Healthcare Llc Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
AU2015373071B2 (en) 2014-12-29 2022-03-31 Toray Industries, Inc. Composition containing nucleic acid molecule stably
US20180066262A1 (en) 2015-03-09 2018-03-08 Caris Science, Inc. Oligonucleotide probes and uses thereof
EP3314027A4 (en) 2015-06-29 2019-07-03 Caris Science, Inc. THERAPEUTIC OLIGONUCLEOTIDES
EP3328873B1 (en) 2015-07-28 2025-09-17 Caris Science, Inc. Targeted oligonucleotides
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
US10731166B2 (en) 2016-03-18 2020-08-04 Caris Science, Inc. Oligonucleotide probes and uses thereof
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
CA3025486A1 (en) 2016-05-25 2017-11-30 Caris Science, Inc. Oligonucleotide probes and uses thereof
EP3332812A1 (en) 2016-12-07 2018-06-13 Rheinische Friedrich-Wilhelms-Universität Bonn Nucleic acid-based assembly and use of the assembly in cancer therapy
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
EP3650045B1 (en) 2017-07-04 2024-11-13 Daiichi Sankyo Company, Limited Drug for retinal degenerative disease associated with photoreceptor degeneration
WO2019210097A1 (en) * 2018-04-25 2019-10-31 Vitrisa Therapeutics, Inc. Aptamers with stability, potency or half-life for enhanced safety and efficacy
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0462145T3 (da) * 1989-03-07 1994-08-08 Genentech Inc Covalente konjugater mellem lipid og oligonucleotid
US6168778B1 (en) * 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US5849479A (en) * 1990-06-11 1998-12-15 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5811533A (en) * 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
WO1996027604A1 (en) * 1995-03-06 1996-09-12 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to secretory phospholipase a2(spla2)
ATE452136T1 (de) * 1995-05-04 2010-01-15 Gilead Sciences Inc Nukleinsäureligand-komplexe

Also Published As

Publication number Publication date
NL300234I2 (nl) 2006-10-02
DE122006000029I1 (de) 2006-10-19
KR100514929B1 (ko) 2005-09-15
DE122006000029I2 (de) 2007-11-08
EP0957929A4 (en) 2003-06-25
FR06C0021I2 (fr) 2007-08-03
NL300234I1 (nl) 2006-09-01
EP0957929B1 (en) 2006-02-22
ATE318143T1 (de) 2006-03-15
IL129497A (en) 2009-06-15
JP4160038B2 (ja) 2008-10-01
WO1998018480A1 (en) 1998-05-07
FR06C0021I1 (enExample) 2006-10-13
DE69735292D1 (de) 2006-04-27
EP1685842A3 (en) 2006-11-29
LU91252I2 (fr) 2006-08-14
AU733674B2 (en) 2001-05-24
DE69735292T2 (de) 2006-10-19
KR20000052697A (ko) 2000-08-25
PT957929E (pt) 2006-06-30
GEP20094799B (en) 2009-10-26
RU2177950C2 (ru) 2002-01-10
EP1685842A2 (en) 2006-08-02
JP2001505191A (ja) 2001-04-17
JP2005046160A (ja) 2005-02-24
CA2269072C (en) 2006-02-14
CA2269072A1 (en) 1998-05-07
NZ334859A (en) 2001-02-23
DK0957929T3 (da) 2006-07-03
AU4990497A (en) 1998-05-22
EP0957929A1 (en) 1999-11-24
IL129497A0 (en) 2000-02-29
JP3626503B2 (ja) 2005-03-09

Similar Documents

Publication Publication Date Title
ES2259188T3 (es) Complejos de ligando de acido nucleico de factor de crecimiento endotelial vascular (vegf).
US6962784B2 (en) Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6051698A (en) Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6168778B1 (en) Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
ES2426160T3 (es) Complejos de ligandos de ácidos nucleicos de factor de crecimiento derivado de plaquetas (PDGF)
US5859228A (en) Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6147204A (en) Nucleic acid ligand complexes
US6465188B1 (en) Nucleic acid ligand complexes
US6011020A (en) Nucleic acid ligand complexes
CA2219119C (en) Nucleic acid ligand complexes
US8071737B2 (en) Nucleic acid ligand complexes
HK1096580A (en) Vascular endothelial growth factor (vegf) nucleic acid ligand complexes
CA2535449A1 (en) Vascular endothelial growth factor (vegf) nucleic acid ligand complexes
JP5637528B2 (ja) 核酸リガンド複合体
ES2502791T3 (es) Aptámeros estabilizados para factor de crecimiento derivado de plaquetas y su uso como productos terapéuticos oncológicos